We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » OIG Tells Novartis It’s Cleared to Offer Kymriah for Free
OIG Tells Novartis It’s Cleared to Offer Kymriah for Free
Novartis is free to pay for low-income patients to receive its pricey CAR-T therapy Kymriah (tisagenlecleucel), and those payments will not be considered illegal.